Biocryst Pharmaceuticals Inc (BCRX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Biocryst Pharmaceuticals reported revenue of $874.8M, up 94.1% from $450.7M the year before. Net income was $263.9M (a 30.2% net margin), or $1.21 per diluted share. Gross margin was 97.8% and operating margin was 39.0%. Operating activities generated $347.4M of cash, leaving $344.9M of free cash flow. At fiscal year end, Biocryst Pharmaceuticals held $514.2M in total assets against $633.3M in total liabilities, including $89.7M of cash and equivalents.
Open the full interactive Biocryst Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Biocryst Pharmaceuticals Key Stats
| Share Price | $8.07 |
|---|---|
| Market Cap | $2.14B |
| P/E Ratio | 6.7 |
| Revenue YoY Growth | +94.1% |
| 52-Week Range | $6.24 – $11.11 |
| Shares Outstanding | 254.5 million (basic, 2026 Q2) |
Biocryst Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Cost of Goods Sold | $1.6M | $7.2M | $6.4M | $4.5M | $12.3M | $19.1M |
| Gross Profit | $16.3M | $149.9M | $264.4M | $326.9M | $438.4M | $855.8M |
| Operating Income | -$174.8M | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| Pre-Tax Income | -$182.8M | -$181.8M | -$244.4M | -$226.2M | -$87.0M | $267.4M |
| Income Tax | $0 | $2.3M | $2.7M | $310,000 | $1.9M | $3.5M |
| Net Income | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| Diluted EPS | -$1.09 | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
Biocryst Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $159.4M | $406.6M | $156.4M | $218.2M |
| Net Income | $12.9M | $245.8M | -$721.8M | $78.4M |
| Diluted EPS | $0.06 | $1.12 | -$2.98 | $0.30 |
Biocryst Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $272.1M | $504.4M | $304.8M | $110.6M | $104.7M | $89.7M |
| Current Assets | $323.8M | $566.1M | $516.5M | $496.0M | $422.0M | $404.3M |
| Total Assets | $334.7M | $588.2M | $550.0M | $517.0M | $490.4M | $514.2M |
| Current Liabilities | $105.7M | $103.7M | $105.5M | $150.0M | $160.4M | $196.1M |
| Total Long-Term Debt | $119.7M | $298.1M | $231.6M | $303.2M | $314.9M | — |
| Total Liabilities | $354.0M | $695.1M | $844.6M | $972.5M | $966.4M | $633.3M |
| Shareholders' Equity | -$19.3M | -$107.0M | -$294.6M | -$455.5M | -$475.9M | -$119.2M |
Biocryst Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$137.2M | -$142.2M | -$161.8M | -$95.1M | -$52.0M | $347.4M |
| Cash From Investing | -$6.9M | $15.8M | -$128.2M | -$131.5M | $52.6M | -$13.7M |
| Cash From Financing | $302.7M | $359.7M | $88.0M | $32.5M | -$5.8M | -$349.9M |
| Free Cash Flow | -$137.7M | -$144.5M | -$163.2M | -$97.3M | -$53.1M | $344.9M |
Figures from Biocryst Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biocryst Pharmaceuticals financials page for every line item.
Biocryst Pharmaceuticals Company Profile
| Ticker | BCRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000882796 |
Frequently Asked Questions
What was Biocryst Pharmaceuticals' revenue in fiscal 2025?
Biocryst Pharmaceuticals (BCRX) reported revenue of $874.8M for fiscal 2025.
What is Biocryst Pharmaceuticals' annual revenue history?
Biocryst Pharmaceuticals' annual revenue by fiscal year: 2020: $17.8M; 2021: $157.2M; 2022: $270.8M; 2023: $331.4M; 2024: $450.7M; 2025: $874.8M.
What was Biocryst Pharmaceuticals' net income in fiscal 2025?
Biocryst Pharmaceuticals reported net income of $263.9M for fiscal 2025.
What was Biocryst Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Biocryst Pharmaceuticals' diluted EPS was $1.21 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biocryst Pharmaceuticals generate in fiscal 2025?
Biocryst Pharmaceuticals generated $344.9M of free cash flow in fiscal 2025.
What was Biocryst Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Biocryst Pharmaceuticals reported revenue of $218.2M.
How many shares of Biocryst Pharmaceuticals are outstanding?
Biocryst Pharmaceuticals reported a weighted average of 254.5 million basic shares outstanding in 2026 Q2.
What is Biocryst Pharmaceuticals' market cap?
Based on its latest closing price, Biocryst Pharmaceuticals (BCRX) has a market capitalization of about $2.14B.
When does Biocryst Pharmaceuticals' fiscal year end?
Biocryst Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Biocryst Pharmaceuticals headquartered?
Biocryst Pharmaceuticals lists its business address in Durham, North Carolina in its SEC filings.
Biocryst Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →